The human heart failure (HF) state leads to alterations in metabolic pathways including worsened glucose metabolism and hyperinsulinemia. Diabetes mellitus is present in 20%-25% of patients with chronic HF in large clinical trials. 1-6 Furthermore, abnormal glucose metabolism and insulin resistance have been shown to be independent predictors of HF incidence, 7-9 severity, 10 and mortality.
tral or may even improve insulin sensitivity. 13, 14 Differential metabolic effects of metoprolol (a β 1 selective antagonist) and carvedilol (a nonselective β-antagonist) have been demonstrated in hypertensive patients with diabetes mellitus. 14 Moreover, a post hoc analysis of the COMET study suggested that new-onset diabetes was more common in patients with HF taking metoprolol as compared with those taking carvedilol. 15 It is possible that the differential metabolic effects between metoprolol and carvedilol may be related to their ability to block β 2mediated hepatic glucose production, although this remains to be investigated.
Previous studies have used the selective β 2 agonist terbutaline and its effects on plasma glucose concentrations as a way to evaluate the presence of β 2 blockade of different β-adrenergic inhibitors. 16 Terbutaline mobilizes glucose into the circulation by stimulating hepatic β 2 receptors. We took advantage of the pharmacology of this selective β 2 agonist to evaluate β 2 -mediated hepatic glucose production in patients with HF.
In this study, we compared β 2 -mediated glucose production, fasting glucose, and insulin resistance between metoprolol and carvedilol during up-titration in patients with American College of Cardiology/American Heart Association (ACC/AHA) Stage C HF.
Methods

PATIENTS
We studied 15 patients with ACC/AHA Stage C, New York Heart Association Functional Class (NYHA FC) II-III HF, who were derived from a previous study in which patients with HF were randomized to receive metoprolol succinate (n = 13) or carvedilol (n = 12). In this prior study, metoprolol succinate (a β 1 -selective agent) and carvedilol (a nonselective agent) were uptitrated in patients with HF, and plasma potassium and glucose concentrations following terbutaline infusions were evaluated to determine dose-related responses of β 2 -AR activity in the 2 β-blockers. 16 In this report, we describe the effect of β-blocker up-titration in nondiabetic participants (n = 9 for metoprolol succinate, n = 6 for carvedilol) on β 2 -mediated glucose production.
All participants were recruited from the University of Utah Advanced Therapies Heart Failure Clinic. Eligibility criteria included evidence of systolic dysfunction (ejection fraction ≤40%) with ACC/AHA Stage C, NYHA Functional Class II-III HF. Participants were on stable optimal drug therapy for HF (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, digoxin, diuretics) and were not on β-blockers. Exclusion criteria included contraindications to β-blockers (active bronchospastic disease, resting heart rate <55 beats/min, systolic blood pressure <90 mm Hg, second-or third-degree heart block), concomitant use of scheduled inhaled β-agonists, use of β-antagonists, prescription or ingestion of diabetes medications within the past 3 months, or use of concomitant antiarrhythmics. In addition, patients with unstable angina or myocardial infarction or bypass surgery within the past 3 months, diagnosis of diabetes, significant renal insufficiency (creatinine >2.5 mg/dL), liver disease (transaminase levels 3 times the upper limit of normal), anemia, active myocarditis, hemodynamically significant valvular heart disease, and hypertrophic or restrictive cardiomyopathy, were also excluded. The protocol was approved by the University of Utah and University of Wisconsin institutional review boards. Informed consent was obtained in accordance with established guidelines for the protection of human subjects.
STUDY PROTOCOL
We evaluated fasting glucose, insulin resistance, and β 2 -mediated glucose production prior to initiation of βblocker therapy and at each titration visit until completion of carvedilol and metoprolol titration. The study methods followed those previously described for studying β 2 -AR mediated glucose production. 16 Participants were admitted to the University of Utah General Clinical Research Center for overnight observation to determine the baseline glucose response to the β 2 agonist terbutaline. All subjects began fasting at midnight. At 0900, terbutaline was infused at 6 μg/kg (maximum 600 μg) for 1 hour. Blood samples for insulin and glucose were taken 15 minutes and 5 minutes prior to infusion, every 10 minutes during terbutaline infusion, every 15 minutes during the first hour postinfusion, and every 30 minutes during the second hour postinfusion (14 samples total). Seated blood pressure and heart rate were measured at each blood draw. After the initial terbutaline infusion and blood sampling, participants were randomized to open-label therapy with either carvedilol (3.125 mg twice daily) or metoprolol succinate (25 mg daily). The starting β-blocker dose was continued for 2 weeks, after which participants returned for a second overnight observation. The assigned β-blocker was administered at 0700, followed by blood sampling and terbutaline infusion at 0900 as performed at the baseline visit. After completion of the infusion and blood draws as described above, the β-blocker dose was doubled for clinically stable patients.
Patients were considered clinically stable if they did not have symptomatic dyspnea, hypotension, or bradycardia.
After 2 weeks at the higher dose, participants returned to the clinical research center for a third overnight observation and terbutaline study. This 2-week cycle continued until each patient reached a target dose of 25 mg twice daily for carvedilol and 200 mg daily for metoprolol succinate. The dosage in patients who could not be titrated to the target dose due to symptomatic dyspnea, hypotension, or bradycardia was titrated to the maximal tolerated dose of the assigned β-blocker. At the fifth visit (week 8), patients returned for their final terbutaline infusion and blood sampling. Fasting insulin concentrations were also obtained at baseline and final visits. Concomitant HF medication doses were to remain constant during β-blocker up-titration. Clinically necessary loop diuretic dose adjustments were allowed.
SAMPLE SIZE CALCULATION
Our primary outcome was the area under the glucose-concentration-time curve during and for 120 minutes after the 1-hour terbutaline infusion (AUC glucose ), compared between the metoprolol and carvedilol groups. Because no comparative data for AUC glucose between carvedilol and metoprolol have previously been reported, we based our sample size on the results of a previous report that showed a significant difference between metoprolol and carvedilol in glycosylated hemoglobin (A1C). 14 In this previous study, the end-of-study A1C was 7.42% versus 7.28% for metoprolol and carvedilol, respectively. Assuming that the standard deviation is 0.09%, which was more conservative than values reported in this previous study, 8 individuals in each β-blocker group were necessary to detect a difference for a 2-sided test, with β = 0.05 and a power of 80%.
STATISTICAL ANALYSES
We analyzed β 2 -mediated glucose production by calculating the area under the glucose-concentration-time curve during and for 120 minutes after the 1-hour terbutaline infusion (AUC glucose ) using the trapezoidal rule. Insulin resistance was calculated using the homeostatic model assessment of insulin resistance (HOMA-IR): fasting values of glucose (mmol/L) x insulin (μ units/mL)/ 22.5. 18 Results that were not normally distributed were log-transformed for statistical analyses and, following back-transformation, were reported in their original units. Differences between groups at baseline were determined with the Student's 2-tailed t-test, and equalities of variances were assessed with the Brown-Forsythe test. For comparisons with unequal variances, p values of Welch analysis of variance (ANOVA) tests are reported, as indicated. Due to the small sample size, we also analyzed the data by the nonparametric Wilcoxon test, in addition to using log-transformed variables, to confirm that nonparametric tests yielded the same conclusions. The effects of β-blocker assignment on glucose parameters after drug titration were analyzed by analysis of covariance (ANCOVA), adjusting for baseline values. The significance of the time trends across the 5 β-blocker titration visits was analyzed using repeated-measures ANOVA. The effect of the β-blocker on time trends was analyzed using 2-way repeated-measures ANOVA. If interactions exist between time and drug assignment, post hoc tests were performed using Tukey HSD. All results were reported as means, or geometric means for log-trans-formed variables, with 95% confidence intervals, and p values less than 0.05 were considered significant. All analyses were performed using JMP 7.0 software (SAS Institute, Cary, NC).
Results
PARTICIPANTS
The sample consisted of 15 participants (5 females, 10 males) with a mean age of 58.9 years (range ~38-84) ( Table 1 ). Mean ejection fraction was 24.5%. No statistically significant differences in demographics, HF severity, medication use, and glucose homeostasis were observed at baseline between the carvedilol and metoprolol groups ( Table 1 ). However, as the sample was small, clinically meaningful differences in patient demographics may be present despite a lack of statistical significance.
All participants were able to achieve the maximum βblocker dose, except for 2 individuals in the metoprolol group who were titrated to 50 mg daily and 1 individual in the carvedilol group who was titrated to 6.25 mg twice daily. Information collected for these 3 subjects was used in the analyses. In addition, 2 participants in the carvedilol group and 2 in the metoprolol group required an increase in their diuretic doses during the study. No significant differences in heart rate (p = 0.087), systolic blood pressure (p = 0.796), and diastolic blood pressure (p = 0.192) time trends were noted between the metoprolol and carvedilol groups during the dose titration visits ( Figure 1 ).
EFFECT OF β β-BLOCKER TITRATION ON FASTING GLUCOSE
Fasting glucose concentrations at baseline were not significantly different between the metoprolol (92.3 mg/dL [95% CI 86.1 to 98.9]) and carvedilol (91.5 mg/dL [95% CI 84.9 to 98.6]) groups (p = 0.85). After completion of β-blocker titration, fasting glucose concentrations for the metoprolol and carvedilol groups were 86.9 mg/dL (95% CI 89.8 to 101.6) mg/dL and 95.7 mg/dL (95% CI 89.8 to 101.6), respectively (p = 0.027, ANCOVA). Fasting glucose profiles during the β-blocker titration visits are shown in Figure 2 .
EFFECT OF β β-BLOCKERS ON FASTING INSULIN AND INSULIN RESISTANCE
Baseline fasting insulin concentration and HOMA-IR were not significantly different between patients receiving carvedilol versus those receiving metoprolol ( 
EFFECT OF β β-BLOCKER TITRATION ON TERBUTALINE-INDUCED GLUCOSE PRODUCTION
Terbutaline-induced glucose production (glucose AUC 0-180 ) at baseline was 18,108.0 mg/dL•min (95% CI 16,299.0 to 19,917.0) in participants taking metoprolol and 18,936.0 mg/dL•min (95% CI 16,720.2 to 21,151.8) in those taking carvedilol (p = 0.54). When all participants were evaluated together, there was a significant reduction in glucose AUC 0-180 across time as dosages of β-blockers increased (p < 0.001). Terbutaline-induced glucose production by dose titration is shown in Figure 3 . After completion of β-blocker titration, glucose AUC 0-180 was 15,546.6 mg/dL•min (95% CI 14,882.4 to 16,212.6) for patients taking metoprolol and 16,351.2 mg/dL•min (95% CI 15,539.4 to 16,839.0) for those taking carvedilol (p = 0.12, ANCO-VA). This difference suggests a divergence between metoprolol and carvedilol at higher doses that is shy of statistical significance (Figure 3) . In fact, a significant reduction in glucose AUC 0-180 compared with baseline was seen only in patients taking metoprolol 100 mg daily (-2424 
Discussion
We sought to determine the effects of β-blockers on glucose dynamics and β 2 -AR-mediated glucose production in patients taking metoprolol succinate or carvedilol at commonly targeted doses. We observed that increased doses of β-blockers resulted in decreased terbutaline-induced glucose production. This occurred in a dose-related fashion for metoprolol, where we noted that increased doses led to significantly reduced terbutaline-induced glucose production. For carvedilol, the reduction in terbutaline-induced glucose production was not significant at any of the time points.
Hepatic glucose production is mediated in part by the actions of the catecholamines norepinephrine and epinephrine on β 2 -AR. Terbutaline is a β 2 -selective agent with weak activity at α receptors. Therefore, changes in glucose concentrations in response to terbutaline are likely due to β 2 -AR-mediated glucose production. Terbutaline infusions offer an opportunity to explore hepatic glucose production in an experimental fashion. Similar to our findings, previous investigations have reported a dose-related reduction in glucose concentrations with terbutaline stimulation and concomitant β-blocker ad- ministration. 16, 19 Carvedilol is nonselective, and metoprolol is β 1 selective at lower doses. Previous studies reported that metoprolol is less β 1 selective at higher doses. 16 According to the adrenergic receptor blocking pharmacology, one would anticipate more pronounced reduction of glucose AUC by carvedilol due to its nonselectivity and affinity to β 2 receptors. 20 This expected enhanced reduction of AUC glucose by carvedilol during terbutaline infusion was not seen in our study. It is possible that carvedilol blocks β 2 receptors to a similar extent through- out its dosing range. As such, it may lead to decreased glucose production initially at lower doses, but the effect may remain constant (as seen in Figure 3 ) if the degree of β 2 blockade is constant as well. Additionally, it is possible that carvedilol treatment leads to β 2 -AR upregulation, as was shown in a murine model of asthma. 21 Moreover, carvedilol serves as a partial inverse agonist at the β 2 -AR, which may lead to upregulated spontaneous active conformation of β 2 -AR, promoting improved receptor coupling. 22 This could explain the reduction of β 2 -mediated glucose production that was evident early, which stabilized through upregulation of β 2 -AR as patients continued to receive carvedilol. In contrast, metoprolol became less β 1 selective at higher doses as titration continued. 16 Metoprolol's blockade of β 2 receptors at higher doses may explain the significant reduction in glucose AUC upon terbutaline infusion at doses of 100 mg daily or above, as compared with baseline.
Reductions in systolic and diastolic blood pressure and heart rate were not significantly different between the β-blocker groups. This suggests that differences in terbutaline-mediated glucose production between the 2 agents are not attributable to hemodynamic differences or varying levels of adherence.
Our finding that metoprolol's loss of β 1 selectivity at doses above 100 mg daily confirm the findings of previous reports 16 and would be clinically relevant in the selection of β-blockers in specific patient populations. For example, in patients with asthma, metoprolol may be prescribed due to its β 1 selectivity, but clinicians should be aware that this drug loses its β 1 selectivity at high doses. In addition, our finding that metoprolol, but not carvedilol, is associated with reduced β 2 -mediated glucose production contributes to the current knowledge of the effects of β-blockers on glucose homeostasis in HF. The findings of this study suggest that β 2 -mediated glucose production does not explain the decreased risk of incident diabetes associated with carvedilol reported by COMET investigators. 15 Hence, other aspects of glucose handling may be important in mediating a reduction of incident diabetes associated with carvedilol. In our study, fasting glucose levels were higher in patients who received carvedilol compared with those who received metoprolol at the conclusion of β-blocker titration. In the COMET study, carvedilol showed a 22% decrease in new-onset diabetes compared with metoprolol tartrate. 15 The GEMINI study, which compared carvedilol and metoprolol in patients with diabetes and hypertension, found similar mean blood glucose concentrations between the 2 agents over 5 months, yet higher hemoglobin A1C values in the metoprolol group. 14 These previous reports of increased incident diabetes and A1C values with metoprolol contrast with our current findings of lower fasting glucose levels in patients with HF assigned to the metoprolol group. This discrepancy may be due to the acute or short-term effects on fasting glucose levels during β-blocker up-titration observed in this 8-week study, as compared with chronic blood glucose changes after titration is completed, as studied in COMET and GEMINI. Additionally, differences in study designs, participant characteristics, and sample size may account for differing study results. We focused on differences in β 2mediated glucose production between metoprolol and carvedilol. Although we expected that carvedilol would have enhanced reduction in β 2 -mediated glucose production compared with metoprolol, in our study, only metoprolol was actually associated with a reduction in β 2 -mediated glucose production. Hence, β 2 -mediated glucose production, as evaluated in this study, does not seem to explain the decreased risk of incident diabetes associated with carvedilol. Future research should concentrate on differences in peripheral insulin sensitivity and glucose utilization between the 2 β-blockers. We did not observe differences in insulin resistance (HOMA-IR) between β-blocker groups during and following dose titrations. These data contrast with those of previous studies in which increased insulin resistance was found for metoprolol tartrate compared with carvedilol. 13,14 Similar to our discrepancies with fasting glucose results in the GEMINI study as mentioned earlier, it is possible that changes in insulin resistance between metoprolol and carvedilol manifest after chronic dosing as examined in prior studies, which we did not measure.
In addition, pharmacogenetic differences among participants may have contributed to the differences in glucose response to terbutaline in this study, particularly from β 2 -AR genetic polymorphisms, as has been shown by previous investigators. 23-25 However, this study was not designed to analyze genetic materials. Future studies should examine genetic associations with metabolic outcomes in patients with HF who are taking β-blockers.
Several limitations should be considered when interpreting the results of this study. Despite the small sample size and limited power due to uneven number of participants in each group, we observed significant results regarding β 2 -mediated glucose production in this study. Nonetheless, results observed should be confirmed in a larger cohort of patients. Due to the small sample size of this study, significant clinical differences in sex, race, and hemodynamic measures between groups may be present that were not detected statistically. However, of note, baseline ejection fraction and metabolic variables (glucose, insulin, HOMA-IR) were very similar between the 2 β-blocker groups. Hence, we are confident that there were not baseline differences in HF severity and metabolic status that would have biased the comparison between the groups. Secondly, we were primarily interested in the effect of carvedilol versus metoprolol titration in patients with HF. Hence, we did not include individuals without HF. Future studies should address effects of β-blockers in HF compared with healthy individuals. Diuretic dose changes may also affect glucose handling. Since adjusting for diuretic dose changes at each visit in a repeated measures analysis poses unique challenges, we did not plan to perform such adjustments and hence did not collect specific diuretic dosage information throughout the study other than whether a diuretic dose increase was necessary. However, the number of individuals requiring an increase in diuretic dose was the same in both treatment groups (2 pts. in each group). Additionally, this was a randomized, but unblinded study. Although it is unlikely that the lack of blinding would affect glucose and insulin values, a blinding procedure would be desirable, especially in any future trials involving more participants. Finally, we evaluated the ef-fects of β 2 -mediated glucose production during up-titration of β-blockers. Future studies should evaluate whether these effects persist during chronic β-blocker use. The results of this exploratory study should be considered hypothesis generating in support of future studies evaluating the effects of specific β-blocker pharmacology on glucose handling in patients with HF.
We conclude that as β-blockade increases, β 2 -AR-mediated glucose production is discordantly reduced between metoprolol succinate and carvedilol. These results should provide an impetus for larger-scale studies. As diabetes and HF coexist at accelerating rates, further research should confirm the effects of β-blocker selection and target doses on glucose handling in patients with HF. J PHARM TECHNOL s VOLUME 25 s MARCH/APRIL 2009 WWW.JPHARMTECHNOL.COM 
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